Quick Answer
RIGEL PHARMACEUTICALS INC reported Cash and Equivalents of $40.58 million for fiscal year 2025.
RIGEL PHARMACEUTICALS INC Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $40.58M | -28.5% |
| 2024 | $56.75M | +73.1% |
| 2023 | $32.79M | +34.0% |
| 2022 | $24.46M | +29.5% |
| 2021 | $18.89M | -37.8% |
| 2020 | $30.37M | +34.9% |
| 2019 | $22.52M | -70.5% |
| 2018 | $76.32M | +99.3% |
| 2017 | $38.29M | +117.2% |
| 2016 | $17.63M | -59.4% |
| 2015 | $43.46M | +185.8% |
| 2014 | $15.20M | -27.1% |
| 2013 | $20.85M | -37.7% |
| 2012 | $33.48M | +79.7% |
| 2011 | $18.63M | +109.9% |
| 2010 | $8.88M | -39.7% |
| 2009 | $14.72M | -68.0% |
| 2008 | $46.01M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $48.53M | -6.1% | -9.1% |
| June 30, 2025 | $53.41M | +48.1% | +16.8% |
| March 31, 2025 | $45.73M | +78.8% | -19.4% |
| December 31, 2024 | $56.75M | +73.1% | +9.8% |
| September 30, 2024 | $51.69M | +13.8% | +43.4% |
| June 30, 2024 | $36.05M | -26.1% | +41.0% |
| March 31, 2024 | $25.57M | -36.5% | -22.0% |
| December 31, 2023 | $32.79M | +34.0% | -27.8% |
- RIGEL PHARMACEUTICALS INC showed a decrease of -28.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2008–2025 period, RIGEL PHARMACEUTICALS INC’s cash and equivalents has declined by 11.8% (from $46.01 million to $40.58 million).
- The most recent figure is from RIGEL PHARMACEUTICALS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: